---
title: "BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 6.988 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265742238.md"
datetime: "2025-11-13T13:33:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265742238.md)
  - [en](https://longbridge.com/en/news/265742238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265742238.md)
generator: "portal-rs"
---

# BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 6.988 M

Revenue: As of FY2025 Q3, the actual value is USD 6.988 M.

EPS: As of FY2025 Q3, the actual value is USD -0.62.

EBIT: As of FY2025 Q3, the actual value is USD -6.167 M.

### Segment Revenue

-   Total revenues for the third quarter of 2025 were $7.0 million, a decrease from $9.0 million in the third quarter of 2024, reflecting a 22% year-over-year decline due to advanced purchases ahead of the October 2024 price increase.
-   Total revenues for the first nine months of 2025 were $24.6 million, slightly down from $24.8 million for the same period in 2024.

### Operational Metrics

-   Operating expenses decreased by 5% year-over-year in the third quarter of 2025 compared to the third quarter of 2024.
-   Cost of revenues decreased by $2.8 million, or 58%, compared to the three months ended September 30, 2024, primarily due to reduced Ameluz costs agreed upon with Biofrontera AG.
-   Selling, general, and administrative expenses were $10.4 million for the third quarter of 2025, up from $8.4 million in the third quarter of 2024, driven by increased legal costs due to patent claims.
-   Net loss for the third quarter of 2025 was $6.6 million, compared to a net loss of $5.7 million for the prior-year quarter.
-   Adjusted EBITDA for the third quarter of 2025 was - $6.0 million compared to - $4.6 million for the third quarter of 2024.

### Cash Flow

-   Cash balance was $3.4 million as of September 30, 2025.

### Unique Metrics

-   The purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG included a new earnout structure reducing payment rates to 12%–15% of U.S. net sales from 25%–35%.

### Outlook / Guidance

-   Biofrontera Inc. anticipates substantial fourth quarter and year-over-year annual revenue growth, supported by growing demand for Ameluz-PDT treatment.
-   The company is positioned for sustained growth and profitability due to a revamped commercial approach and recent transactions enhancing gross margins.
-   The acquisition of U.S. rights for Ameluz and RhodoLED lamps is expected to significantly enhance long-term profitability.

### Related Stocks

- [BFRIW.US](https://longbridge.com/en/quote/BFRIW.US.md)

## Related News & Research

- [3,759 Shares in Ferrari N.V. $RACE Acquired by X Square Capital LLC](https://longbridge.com/en/news/296700358.md)
- [Korea Investment CORP Increases Stock Position in L3Harris Technologies Inc $LHX](https://longbridge.com/en/news/296698330.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Danske Bank A S Invests $252.05 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296695181.md)
- [BlackRock Inc. Invests $938.29 Million in Affiliated Managers Group, Inc. $AMG](https://longbridge.com/en/news/296694541.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**